These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 26549592)

  • 21. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
    Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
    Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells.
    Giovannetti E; Backus HH; Wouters D; Peters GJ
    Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):740-5. PubMed ID: 18600534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
    Chang SC; Lin JK; Lin TC; Liang WY
    Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells.
    Chen D; Yu Z; Zhu Z; Lopez CD
    Cancer Res; 2006 Apr; 66(7):3485-94. PubMed ID: 16585172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
    Abarzúa P; LoSardo JE; Gubler ML; Neri A
    Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].
    Ishida H; Sadahiro S; Tajima T; Makuuchi H
    Nihon Rinsho; 2003 Sep; 61 Suppl 7():233-6. PubMed ID: 14574888
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of nonsteroidal anti-inflammatory drug-activated gene-1 in docetaxel-induced cell death of human colorectal cancer cells with different p53 status.
    Kim IY; Park SY; Kang Y; Thapa D; Choi HG; Kim JA
    Arch Pharm Res; 2011 Feb; 34(2):323-30. PubMed ID: 21380817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LKB1 loss at transcriptional level promotes tumor malignancy and poor patient outcomes in colorectal cancer.
    He TY; Tsai LH; Huang CC; Chou MC; Lee H
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S703-10. PubMed ID: 24879590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations of K-ras and p53 mutations in colorectal cancer patients in Central Europe.
    König EA; Köves I; Raşinariu A; Popp AR; Kusser WC; Soyonki K; Kovács A; Glickman BW; Jeney A; Marcsek ZL
    J Toxicol Environ Health A; 2001 Mar; 62(5):333-47. PubMed ID: 11261896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. XEDAR as a putative colorectal tumor suppressor that mediates p53-regulated anoikis pathway.
    Tanikawa C; Furukawa Y; Yoshida N; Arakawa H; Nakamura Y; Matsuda K
    Oncogene; 2009 Aug; 28(34):3081-92. PubMed ID: 19543321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
    Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status.
    Wang Z; Li Y; Liu ET; Yu Q
    Biochem Biophys Res Commun; 2004 Sep; 322(2):609-13. PubMed ID: 15325273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberration of p53 and DCC in gastric and colorectal cancer.
    Kataoka M; Okabayashi T; Johira H; Nakatani S; Nakashima A; Takeda A; Nishizaki M; Orita K; Tanaka N
    Oncol Rep; 2000; 7(1):99-103. PubMed ID: 10601600
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: immunohistochemical study.
    Ajioka Y; Watanabe H; Matsuda K
    J Gastroenterol; 1995 Nov; 30 Suppl 8():33-5. PubMed ID: 8563884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tobacco, alcohol, and p53 overexpression in early colorectal neoplasia.
    Terry MB; Neugut AI; Mansukhani M; Waye J; Harpaz N; Hibshoosh H
    BMC Cancer; 2003 Nov; 3():29. PubMed ID: 14604438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic anticancer activity of capsaicin and 3,3'-diindolylmethane in human colorectal cancer.
    Clark R; Lee J; Lee SH
    J Agric Food Chem; 2015 May; 63(17):4297-304. PubMed ID: 25876645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Peripheral blood p53 single nucleotide polymorphism analysis for early diagnosis of colorectal carcinoma].
    Liu Q; Lai ZS; Wnag W; Zhang Y; Zhou M
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1939-40. PubMed ID: 18159026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis.
    Leahy DT; Salman R; Mulcahy H; Sheahan K; O'Donoghue DP; Parfrey NA
    J Pathol; 1996 Dec; 180(4):364-70. PubMed ID: 9014855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial and nutritional risk factors for p53 overexpression in colorectal cancer.
    Freedman AN; Michalek AM; Marshall JR; Mettlin CJ; Petrelli NJ; Black JD; Zhang ZF; Satchidanand S; Asirwatham JE
    Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):285-91. PubMed ID: 8722220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin.
    He ZY; Shi CB; Wen H; Li FL; Wang BL; Wang J
    Cancer Invest; 2011 Mar; 29(3):208-13. PubMed ID: 21314329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.